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Abstract
Background: Leptin, a 16 kDa polypeptide hormone, implicated in various physiological processes, exerts its
action through the leptin receptor, a member of the class I cytokine receptor family. Both leptin and leptin
receptor have recently been implicated in processes leading to breast cancer initiation and progression in animal
models and humans. An A to G transition mutation in codon 223 in exon 6 of the leptin receptor gene, resulting
in glutamine to arginine substitution (Gln223Arg), lies within the first of two putative leptin-binding regions and
may be associated with impaired signaling capacity of the leptin receptor. This study was designed to assess the
role of this polymorphism in breast cancer susceptibility in Nigerian women.
Methods: We utilized a polymerase chain reaction (PCR)-based restriction fragment length polymorphism
(RFLP) assay to evaluate the association between the Gln223Arg polymorphism of the leptin receptor gene and
breast risk in Nigeria in a case control study involving 209 women with breast cancer and 209 controls without
the disease. Study participants were recruited from surgical outpatient clinics and surgical wards of four University
Teaching Hospitals located in Midwestern and southeastern Nigeria between September 2002 and April 2004.
Results: Premenopausal women carrying at least one LEPR 223Arg allele were at a modestly increased risk of
breast cancer after adjusting for confounders (OR = 1.8, 95% confidence interval [CI] 1.0–3.2, p = 0.07). There
was no association with postmenopausal breast cancer risk (OR = 0.9, 95% CI 0.4–1.8, p = 0.68).
Conclusion: Our results suggest that the LEPR Gln223Arg polymorphism in the extracellular domain of the LEPR
receptor gene is associated with a modestly increased risk of premenopausal breast cancer in Nigerian women.
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Background
Leptin, a 16 kDa polypeptide hormone produced pre-
dominantly by white adipose tissue [1], plays an impor-
tant role in body weight homeostasis through effects on
food intake and energy expenditure [2,3]. In addition to
the regulation of body weight, leptin also influences
hematopoiesis, reproduction, angiogenesis, and immune
processes [4-6]. Leptin exerts its physiological action
through the leptin receptor (LEPR), a member of the class
I cytokine receptor family. The leptin receptor is a single
transmembrane protein and has several alternatively
spliced isoforms (one long isoform and several short iso-
forms) that are distributed in many tissues [7,8]. LEPRs
have been detected in human breast epithelial cell lines,
breast cancer-derived cell lines (T47-D and MCF-7) and in
human breast cancer tissue specimens [9-11]. In addition,
leptin consistently stimulates the proliferation of benign
and malignant epithelial breast cells in vitro as measured
by DNA synthesis, cellular density and up-regulation of
downstream regulators of cellular proliferation [9-12].
Several single nucleotide polymorphisms (SNPs) in the
LEPR gene have been described. Chung et al. [13] identi-
fied three allelic variants associated with amino acid
changes (Lys109Arg, Gln223Arg, and Lys656Asn), three
silent mutations (nt 1222 T→C, nt 3217 A→G, and nt
3250 G→A), and four intronic sequence variants. All three
amino acids (Lys109Arg, Gln223Arg, and Lys656Asn) are
conserved among rat, mouse, and human species [14,15],
but only Gln223Arg and Lys656Asn result in changes in
charge (neutral to positive and positive to neutral, respec-
tively) and are, therefore, most likely to have functional
consequences. The Gln223Arg polymorphism is within
the region encoding the extracellular domain of the leptin
receptor and therefore, the amino acid change affects all
forms of the receptor. It has been shown that the LEPR
Gln223Arg polymorphism is associated with variation in
ligand binding; higher levels of ligand binding activity has
been demonstrated in individuals homozygous for the G
(LEPR Arg223Arg) allele than for carriers of the A (LEPR
223Gln) allele [16].
Despite these premises, very few studies have considered
the role of serum leptin levels and polymorphisms in lep-
tin and LEPR genes in breast cancer risk [17-23]. Four
studies [17-20] on plasma leptin levels and breast cancer
risk have shown conflicting results; one in the Italian pop-
ulation [17] and another among the Chinese [18]
reported significant increased risk of breast cancer with
higher serum leptin levels while two other studies [19,20]
in the Greek and U.S. populations, respectively, found no
associations. Of two studies that evaluated relationship
between LEPR Gln223Arg polymorphism and serum lep-
tin levels, one study among college students in Greece
[21] reported significantly higher leptin levels in heterozy-
gote (LEPR  Gln223Arg) and homozygote (LEPR
Arg223Arg) carriers of the G allele; the second study by
Quinton et al. [16] among postmenopausal British
women reported lower leptin levels among carriers of the
G allele. Only two studies [22,23] have examined allelic
variants of the LEPR genes in breast cancer susceptibility;
one [22] reported positive association among Tunisian
women while the other [23] found no association
between these variants and breast cancer risk in Korean
women. We are unaware of any study of this susceptibility
marker and breast cancer risk in black populations.
Although, several polymorphisms have been described in
the LEPR gene, we have chosen in this exploratory study
to evaluate the role of the LEPR  Gln223Arg polymor-
phism in breast cancer susceptibility in Nigerian women
since it is the most studied functional LEPR gene polymor-
phism in human subjects.
Methods
Subjects
The recruitment of participants for this study from four
University Teaching Hospitals located in southern Nigeria
(University of Benin Teaching Hospital, Benin City;
Nnamdi Azikiwe University Teaching Hospital, Nnewi;
University of Nigeria Teaching Hospital, Enugu; and Uni-
versity of Port Harcourt Teaching Hospital, Port Harcourt
between September 2002 and April 2004) has been
described elsewhere [24,25]. Briefly, 209 women with
confirmed breast cancer and 209 age-matched control
subjects without the disease or any other malignancy were
recruited during surgical outpatient visits or hospital
admissions. Control subjects were being treated in the
same hospitals for non-malignant diseases including
unintentional injuries, acute inflammatory diseases such
as chronic duodenal ulcer, appendicitis, pelvic inflamma-
tory disease and urolithiasis. The study protocol was
approved by the Institutional Review Board of University
of Pittsburgh and the Ethics and Research Committees of
the Nigerian institutions prior to commencement.
Women with suspected breast cancer without histological
confirmation and those that refused sample donation
were excluded from the study.
Study participants signed informed consent after detailed
explanation of the purpose, risks and benefits, confidenti-
ality and rights of participants prior to recruitment. Data
in respect of reproductive history, demographic character-
istics, occupational exposure to pesticides and fertilizers
and lifestyle choices including alcohol consumption and
cigarette smoking were obtained using interviewer-
administered questionnaires. Anthropometric measure-
ments including height, weight, waist and hip circumfer-
ences were taken at the end of the interview.
Sample Donation and Preparation
Ten milliliters (ml) blood sample was collected into one
10 ml K3-EDTA vacutainer tube from each of the studyBMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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participants at the end of the interview. The buffy coat was
prepared by centrifuging whole blood 2500 × g for 10 min
at room temperature. All the samples were stored at -20°C
in the Nigerian coordinating center at the University of
Benin Teaching Hospital and later shipped to University
of Pittsburgh in dry ice. Samples were stored at -80°C at
the University of Pittsburgh until DNA extraction. DNA
extraction from buffy coats (and clots for subjects with no
buffy coats) was carried out using QIAamp DNA Mini Kits
(for buffy coats) and QIAamp DNA Midi Kits (for blood
clots) protocols (QIAGEN Inc, Valencia, CA). The
extracted DNA was stored at 4°C until used for polymer-
ase chain reaction (PCR) and restriction fragment length
(RFLP) analysis.
PCR and RFLP analysis
Genomic DNA from the cases and control subjects were
analyzed for the presence of the A to G mutation at codon
223 of the LEPR gene by a PCR-based restriction fragment
length polymorphism (RFLP) assay. PCR amplification of
an 80 bp fragment of the LEPR gene, including part of
exon 6 that contains the polymorphism was carried out
using forward primer: AAACTCAACGACACTCTCCTT and
reverse primer: TGAACTGACATTAGAGGTGAC. A 50 μl
PCR reaction mixture containing 2 μl of genomic DNA, 5
μl of deoxynucleotide triphosphates, 3 μl each of forward
and reverse primers, 5 μl of 10× buffer, 1.5 μl of MgCl2
and 0.5 μl of Taq polymerase was placed in a thermocy-
cler. After denaturing for 5 min at 95°C, the DNA was
amplified for 35 cycles at 95°C for 30 sec, 59°C for 45 sec,
and 72°C for 60 sec, followed by a 5 min extension at
72°C. A positive control containing genomic DNA and a
negative control containing everything except DNA were
included in the PCR experiment. Five μl of each PCR prod-
uct, including the controls, were verified on a 3% agarose
gel to ensure that the expected 80 bp product was gener-
ated.
Restriction digest for the DNA fragment was carried out
using Msp 1 restriction enzyme. Fifteen μl of the PCR
product was digested for 16 h overnight at 37°C with 10
units of Msp 1 (New England Biolabs). The product of the
restriction digest was mixed with 10 μl of loading dye and
verified on a 3% agarose gel (with Ethidium bromide)
electrophoresis in a 1× Tris-Borate-EDTA buffer at 200 V
for 60 min. The presence of an A at position 668 (LEPR
codon 223) generated a unique 80 bp fragment, while the
80 bp fragment was divided into unique 58 bp and 22 bp
fragments when position 668 contains a G. The gels were
visualized by UV light and the RFLP gel electrophoresis
products were read by two independent persons who were
unaware of the identities of samples as either cases or con-
trols. DNA extraction and RFLP assays employing Msp 1
restriction enzyme were successful in 209 cases and 209
control subjects; therefore the analysis is restricted to this
sample of women.
Statistical Analyses
Statistical analysis was carried out using the Statistical
Analysis System (SAS) software (Version 8.0). Although
the original data was matched by age, the analysis of the
genetic data was conducted on the unmatched sample,
since DNA was not available on all the study participants.
Therefore an unmatched analysis was conducted and an
adjustment for age was performed. Unconditional logistic
regression was used to assess the association between the
LEPR Gln223Arg genotypes and breast cancer risk in the
whole sample. Stratified analyses according to menopau-
sal status were then carried out. Relevant risk factors that
were identified as significant predictors of breast cancer




A total of 418 female participants were recruited from the
surgical outpatient clinics and surgical wards of the four
University Teaching Hospitals in southern Nigeria. Two
hundred and nine of them were being managed for vari-
ous stages of breast cancer while the remaining 209
women, being treated for various non-malignant diseases
in the same institutions served as control subjects. The
ages of the cases and control subjects were similar with
mean ages of 46.1 ± 12.63 years and 47.1 ± 13.50 years for
cases and controls, respectively. Details on the associa-
tions between anthropometric, demographic and repro-
ductive variables are reported elsewhere [26,27].
Allele and Genotype Frequencies in All women
Our results indicate that the LEPR Gln223Arg variant is
highly polymorphic in the Nigerian population. The dis-
tribution of the LEPR Gln223Arg alleles and genotypes are
shown in Table 1. When all study participants were con-
sidered together, the distribution of the LEPR  223Gln
allele was similar in cases and controls with allele frequen-
cies of 0.49 and 0.51, respectively while the frequency of
the LEPR 223Arg allele was 0.51 and 0.49, respectively.
The homozygous LEPR Gln223Gln genotype was slightly
less common in the cases compared to the controls with
genotype frequencies of 0.22 and 0.27, respectively while
the heterozygous LEPR Gln223Arg genotype was equally
distributed among cases and controls with frequency of
0.51 in both cases and control subjects. The homozygous
Arg223Arg genotype was slightly more common in the
cases compared to the controls with frequencies of 0.27
and 0.22, respectively. The distribution of the LEPR
223Gln and 223Arg alleles among the controls were in
Hardy-Weinberg equilibrium overall and in both premen-
opausal and postmenopausal women.BMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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Premenopausal Women
The DNA extraction and RFLP Msp 1 assays were success-
ful in 114 premenopausal breast cancer cases and 121
control subjects. The LEPR 223Gln allele was less frequent
in premenopausal breast cancer cases compared to those
without breast cancer with allele frequencies of 0.46 and
0.54, respectively. The wild-type LEPR Gln223Gln geno-
type was less frequent in the women with breast cancer
compared to those without the disease, with genotype fre-
quencies of 0.20 and 0.31, respectively. (Table 1).
Postmenopausal Women
There was no apparent difference in the distribution of the
LEPR 223Gln and LEPR 223Arg alleles in postmenopausal
women with breast cancer compared to the control sub-
jects. The LEPR  Gln223Gln genotype frequencies were
0.24 in cases and 0.21 in the controls as shown in Table 1.
LEPR Gln223Arg Genotypes and Breast Cancer Risk in All 
Women
Compared to women with the LEPR Gln223Gln geno-
type, those harboring the heterozygous LEPR Gln223Arg
genotype (OR = 1.2, 95% CI 0.8–2.0, p = 0.42) and the
homozygous mutant LEPR  Arg223Arg genotype (OR =
1.5, 95% CI 0.8–2.6, p = 0.16) had no significant
increased risk of breast cancer.
The presence of at least one LEPR 223Arg allele (LEPR
Gln223Arg + LEPR Arg223Arg genotypes) was not associ-
ated a significant risk of breast cancer in these women (OR
Table 1: Distribution of Leptin receptor (LEPR) alleles and genotypes in relation to breast cancer risk (unconditional logistic 
regression)
Cases Controls OR (95% CI) P-value OR (95% CI)* P-value
All women (n = 209) (n = 209)
Allele frequencies
LEPR (Gln) 0.49 0.51
LEPR (Arg) 0.51 0.49
Genotype frequencies
LEPR (Gln/Gln) 46 (22.0) 56 (26.8) 1.0
LEPR (Gln/Arg) 107 (51.2) 107 (51.2) 1.2 (0.8–2.0) 0.42 1.2 (0.8–2.0) 0.40
LEPR (Arg/Arg) 56 (26.8) 46 (22.0) 1.5 (0.8–2.6) 0.16 1.6 (0.9–3.2.8) 0.13
LEPR (Gln/Gln 46 (22.0) 56 (26.8) 1.00
LEPR (Gln/Arg) + (Arg/Arg) 163 (78.0) 153 (73.2) 1.3 (0.8–2.0) 0.26 1.3 (0.8–2.1) 0.23
Pre-menopausal women (n = 114) (n = 121)
Allele frequencies
LEPR (Gln) 0.46 0.54
LEPR (Arg) 0.54 0.46
Genotype frequencies
LEPR (Gln/Gln) 23 (20.2) 38 (31.4) 1.00
LEPR (Gln/Arg) 60 (52.6) 54 (44.6) 1.8 (1.0–3.5) 0.06 1.8 (0.9–3.3) 0.07
LEPR (Arg/Arg) 31 (27.2) 29 (24.0) 1.8 (0.9–3.6) 0.12 1.8 (0.8–3.7) 0.14
LEPR (Gln/Gln 23 (20.2) 38 (31.4) 1.00
LEPR (Gln/Arg) + (Arg/Arg) 91 (79.8) 83 (68.6) 1.8 (1.0–3.3) 0.05 1.8 (1.0–3.2) 0.07
Postmenopausal women (n = 95) (n = 88)
Allele frequencies
LEPR (Gln) 0.49 0.51
LEPR (Arg) 0.51 0.49
Genotype frequencies
LEPR (Gln/Gln) 23 (24.2) 18 (20.5) 1.00
LEPR (Gln/Arg) 47 (49.5) 53 (60.2) 0.7 (0.3–1.4) 0.33 0.7 (0.4–1.5) 0.42
LEPR (Arg/Arg) 25 (26.3) 17 (19.3) 1.2 (0.5–2.8) 0.75 1.2 (0.5–3.0) 0.62
LEPR (Gln/Gln 23 (24.2) 18 (20.5) 1.00
LEPR (Gln/Arg) + (Arg/Arg) 72 (75.8) 70 (79.5) 0.8 (0.4–1.6) 0.54 0.9 (0.4–1.8) 0.68
*Adjusted for age and waist/hip ratio (WHR)BMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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= 1.3, 95% CI 0.8–2.0, p = 0.26). Adjusting for waist/hip
ratio, a surrogate measure of obesity did not significantly
alter the risk profile in these women as shown in Table 1.
Premenopausal Women
Among premenopausal women, there was a marginally
increased risk of breast cancer with the LEPR 223Arg allele
(LEPR Gln223Arg + LEPR Arg223Arg): OR = 1.8, 95% CI
1.0–3.3, p = 0.05 (Table 1). The heterozygous LEPR
Gln223Arg genotype was associated with a modestly
increased risk of breast cancer (OR = 1.8, 95% CI 1.0–3.5,
p = 0.06). The homozygous LEPR Arg223Arg genotype
was also associated with some modest increase in breast
cancer risk (OR = 1.8, 95% CI 0.9–3.6, p = 0.12). These
risk profiles were unaltered when the analysis was
adjusted for waist/hip ratio and age (LEPR Gln223Arg +
LEPR Arg223Arg OR = 1.8, 95% CI 1–3.2, p = 0.07; LEPR
Gln223Arg genotype OR = 1.8, 95% CI 0.9–3.3, p = 0.07
and LEPR Arg223Arg genotype OR = 1.8, 95% CI 0.8–3.7,
p = 0.14).
Postmenopausal Women
Among postmenopausal women there was no significant
relationship between the LEPR Gln223Arg polymorphism
and breast cancer risk (Table 1). Adjusting for waist/hip
ratio did not significantly alter the risk profiles.
Discussion
The results of our study showed that the LEPR Gln223Arg
variant is highly polymorphic in the Nigerian population.
The LEPR 223Arg allele frequency of 0.49 in our study par-
ticipants is higher than figures reported in Caucasians
(0.45), Pima Indians (0.32), Arabs (0.34) but much lower
than figures in Asian populations (0.85) [28]. Although a
study of mixed U.S. population by Chung et al. [13]
reported little difference in LEPR 223Arg allele frequency
by racial groups, the study recruited only 26 blacks and
racial admixture in the U.S. population may partly
account for their finding. The International Hapmap
Project reported LEPR 223Arg allele frequencies of 0.61
among Yorubas in Ibadan, Nigeria and 0.53 in African
Americans. [29]
The evaluation of the relationship of the LEPR Gln223Arg
polymorphism and breast cancer risk showed that pre-
menopausal women carrying at least one LEPR 223Arg
allele were at a modestly increased risk of breast cancer
(OR = 1.8, 95% CI 1.0–3.3, p = 0.05); the risk was unal-
tered after adjusting for waist/hip ratio and age (OR = 1.8,
95% CI 1.0–3.2, p = 0.07). There was no association
between the LEPR Gln223Arg polymorphism and breast
cancer risk in postmenopausal women. Two studies
[22,23] evaluated the LEPR Gln223Arg polymorphism in
relation to breast cancer risk; one [22] in the Tunisia pop-
ulation reported significantly increased risk in both pre-
menopausal and postmenopausal women in a dose
dependent manner (OR = 1.68, 95% CI 1.12–2.50 and
OR = 2.26, 95% CI 1.31–3.90 for the LEPR Gln223Arg
and Arg223Arg genotypes, respectively). In addition, the
authors noted that the presence of the LEPR 223Arg allele
was associated with poorer overall survival. The second
study by Woo et al. [23] found no association between the
polymorphism and breast cancer risk in both premeno-
pausal and postmenopausal Korean women (OR = 0.54,
95% CI 0.19–1.81). The authors noted the rarity of the
LEPR 223Gln allele in the Korean population (allele fre-
quency, 0.09) and the small sample size of their study (45
breast cancer cases and 45 control subjects). Some inves-
tigators [16,18,21] have examined the relationship
between variants of the LEPR Gln223Arg polymorphism
and serum levels of leptin since there is some evidence
associating serum leptin levels with breast cancer risk
[17,18]. In a study involving 118 college students in
Greece (62 females and 56 males), Yiannkouris et al. [21]
reported significantly higher serum leptin levels in indi-
viduals who were homozygous LEPR  Arg223Arg com-
pared with those harboring at least one LEPR  223Gln
allele. Another study of 220 postmenopausal women in
the U.K. found significant association between serum lep-
tin levels and the LEPR genotype [16].
Although the actual mechanisms of leptin's role in breast
cancer risk are not completely known, several lines of evi-
dence provide support for leptin's broader physiological
role, including the regulation of several neuroendocrine
axes, some of which play a significant role in the patho-
genesis of breast cancer. Leptin treatment corrects the
hypogonadism of leptin-deficient ob/ob mice [30,31] and
starved normal mice [32], accelerates the onset of puberty
in rodents and increasing leptin levels may signal the
onset of puberty in boys and girls [33,34]. In addition,
leptin's pulsatile secretion is synchronized with the pulsa-
tility of luteinizing hormone and estradiol in normal
women [35]. Leptin has been shown to regulate GH secre-
tion [36] and serum leptin levels have been associated
with circulating IGF-1 and IGFBP-3 levels in normal and
GH-deficient humans [34,37]. In addition, circulating
leptin levels have been associated with certain life-style
factors, such as smoking and alcohol intake [34]. Interest-
ingly, the above endocrine axes and life-style factors have
also been implicated in the pathogenesis of breast cancer
via leptin's interaction with IGF-I and IGFBP-3 [38,39].
Tumor markers that are elevated in breast cancer can
upregulate leptin production. These factors, including
TNF-α, IL-1α, IL-1β, VEGF, and fibroblast growth factor 2
(FGF-2), raise leptin levels and promote tumor growth
and differentiation [40,41]. In experimental studies, lep-
tin consistently stimulated human breast epithelial cell
lines and breast cancer-derived cell lines resulting inBMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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increased DNA synthesis evaluated by thymidine incorpo-
ration test and increased cellular growth estimated by cel-
lular density [9-12]. Several down-stream effects of leptin
signaling leading to cellular proliferation were also
observed including increased expression of phosphor-
ylated signal transducers (STAT3), extracellular signal-reg-
ulated kinase (ERK), mitogen-activated protein kinases
(MAPK) and transcript activator protein (AP-1), and also
increased expression of cyclin dependent kinase-2 and
cyclin D1, two cell-cycle regulating proteins [9,10]. It has
been suggested that the single amino acid change in the
LEPR gene (LEPR Gln223Arg), a glutamine for an arginine
with a change from neutral to positive, could affect the
functionality of the receptor and alter its signaling capac-
ity [13,42,43]. The finding of higher leptin binding activ-
ity (LBA) levels in homozygous carriers of the G allele
(LEPR Arg223Arg) and higher levels of leptin in the LEPR
Arg223Arg homozygotes and our finding of increased pre-
menopausal breast cancer risk in women carrying the
LEPR 223Arg allele provides supportive evidence for this
proposition. It is possible that the leptin polymorphism is
in linkage disequilibrium with other genes that play a role
in breast cancer risk.
An important observation is the paucity of epidemiologi-
cal literature on the role of polymorphisms in the leptin
receptor (LEPR) gene in breast cancer susceptibility in
most populations and its complete absence in sub-Saha-
ran African populations. Much has been said about the
mechanisms of leptin-induced carcinogenesis in animal
models and correlation of serum leptin levels with breast
cancer risk [17-20]. The effect of genotypes such as LEPR
Gln223Arg polymorphism on breast cancer may vary
from one population to the other as a result of marked dif-
ferences in the distribution of the alleles in different pop-
ulations. The finding of interaction between LEPR
Gln223Arg genotypes and menopausal status and obesity
may also partly explain the differences in reports from var-
ious populations. In the developed countries with a much
higher percentage of postmenopausal breast cancer and a
higher proportion of obese women, LEPR Gln223Arg pol-
ymorphism may be expected to have more impact on risk
of the disease compared to the Nigerian population with
a lower prevalence of obesity. Some of the limitations of
this study include use of both incident and prevalent cases
of breast cancer. Given the report of poorer prognosis
associated with the LEPR 223Arg allele in some studies, it
is possible that some patients harboring this allele might
have died earlier leaving us with more patients with the
LEPR  223Gln allele. However, such a bias if prevent
would result in underestimation of the risk associated
with the putative high risk LEPR 223Arg allele. There is
currently no breast cancer screening program in Nigeria;
therefore patients with early pre-clinical disease may have
been missed in our study. Use of hospital controls is
necessitated by the limited research infrastructure such as
poor communication facilities and lack of population-
based cancer registries in developing countries such as
Nigeria.
Another issue of concern is the sample size of this study.
In fact, we estimate that with an allele frequency of .49 in
all women combined, a sample size of 139 cases and con-
trols provides a power of 80% to detect an odds ratio (OR)
of 2.0. There were a total of 209 cases and 209 controls in
our study population indicating that this sample size has
adequate statistical power to detect an OR of 2.0. How-
ever, when we stratify by menopausal status, the number
of cases and controls become much lower, thus decreasing
the statistical power of the study. For example, a sample
size of 137 premenopausal cases and 137 premenopausal
controls would be adequate to detect an odds ratio of 2.0
while there were 114 premenopausal cases and 121 pre-
menopausal controls in our study. It is possible that vari-
ations in LEPR polymorphisms and other low penetrance
genes may contribute to the marked worldwide variation
in breast cancer incidence, with the highest age-standard-
ized incidence rate (ASR) in North America (ASR, 99.4 per
100,000) and the lowest age-standardized incidence rates
in sub-Saharan Africa (ASR, 27.8 per 100,000 in West
Africa, 19.5 per 100,000 in East Africa and 16.5 per
100,000 in Central Africa) [44].
Conclusion
In conclusion, this study has demonstrated a modestly
increased risk of premenopausal breast cancer in women
harboring the LEPR 223Arg allele of the LEPR Gln223Arg
polymorphism of the leptin receptor gene. To the best of
our knowledge, ours is the first study to provide informa-
tion on the role of LEPR Gln223Arg polymorphism in
breast cancer risk in sub-Saharan African women, a popu-
lation characterized by paucity of epidemiological litera-
ture on the determinants of breast cancer and other
malignancies.
Abbreviations
LEPR: Leptin receptor; DNA: Deoxyribonucleic acid; PCR:
Polymerase chain reaction; SNP: Single Nucleotide Poly-
morphism; RFLP: Restriction fragment length polymor-
phism; STAT3: Signal transducers of activation of
transcription; ERK: Extracellular signal-regulated kinase;
MAPK: Mitogen-activated protein kinase; SAS: Statistical
analysis systems
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MNO, CHB, ET, SJG, REF, LHK, participated in conceptu-
alization, design of the study and preparation of manu-BMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
Page 7 of 8
(page number not for citation purposes)
script. MNO, ERE, SNA, and EEU recruited study
participants from Nigeria and organized the transfer of
biological samples to the University of Pittsburgh. MNO,
CHB, ET, SJG and JMZ carried out the genetic analysis.
Acknowledgements
This study was supported by a post-doctoral grant awarded to Michael N. 
Okobia by the US Army Medical and Materiel Command's Breast Cancer 
Research Program (Award Number: DAMD17-02-1-0551). We are grate-
ful to the staff of the Departments of Surgery of the Nigerian Study Sites 
including University of Benin Teaching Hospital, Benin City; Nnamdi 
Azikiwe University Teaching Hospital, Nnewi; University of Nigeria Teach-
ing Hospital, Enugu; and the University of Port Harcourt Teaching Hospital, 
Port Harcourt, for all their assistance during the recruitment of study par-
ticipants. Special thanks to the staff of the Department of Epidemiology, 
University of Pittsburgh for their invaluable assistance throughout the con-
duct of this study.
References
1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM:
Positional cloning of the mouse obese gene and its human
homologue.  Nature 1994, 372:425-432.
2. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant
mouse OB protein: evidence for a peripheral signal linking
adiposity and central neural networks.  Science 1995,
269:546-549.
3. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D,
et al.: Weight-reducing effects of the plasma protein encoded
by the obese gene.  Science 1995, 269:543-546.
4. Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W:
A role for leptin and its cognate receptor in hematopoiesis.
Curr Biol 1996, 6:1170-1180.
5. Bouloumie A, Drexler HC, Lafontan M, Busse R: Leptin, the prod-
uct of Ob gene, promotes angiogenesis.  Circ Res 1998,
83:1059-1066.
6. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al.:
Leptin regulates proinflammatory immune responses.  FASEB
J 1998, 12:57-65.
7. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI,
et al.: Abnormal splicing of the leptin receptor in diabetic
mice.  Nature 1996, 379:632-635.
8. Tartaglia LA: The leptin receptor.  J Biol Chem 1997,
272:6093-6096.
9. Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin – a growth factor
in normal and malignant breast cells and for normal mam-
mary gland development.  J Natl Cancer Inst 2002, 94:1704-1711.
10. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC,
Pecquery R, Giudicelli Y: Leptin mediates a proliferative
response in human MCF7 breast cancer cells.  Biochem Biophys
Res Commun 2002, 293:622-628.
11. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J: Identification
of leptin receptors in human breast cancer: functional activ-
ity in the T47-D breast cancer cell line.  Mol Cell Endocrinol 2002,
188:219-226.
12. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Jamali
M, et al.: Leptin and high glucose stimulate cell proliferation in
MCF-7 human breast cancer cells: reciprocal involvement of
PKC-alpha and PPAR expression.  Biochim Biophys Acta 2002,
1592:107-116.
13. Chung WK, Power-Kehoe L, Chua M, Chu F, Aronne L, Huma Z, et
al.: Exonic and intronic sequence variation in the human lep-
tin receptor gene (LEPR).  Diabetes 1997, 46:1509-1511.
14. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et
al.: Identification and expression cloning of a leptin receptor,
OB-R.  Cell 1995, 83:1263-1271.
15. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al.:
Leptin receptor missense mutation in the fatty Zucker rat.
Nat Genet 1996, 13:18-19.
16. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI: A single
nucleotide polymorphism (SNP) in the leptin receptor is
associated with BMI, fat mass and leptin levels in postmeno-
pausal Caucasian women.  Hum Genet 2001, 108:233-236.
17. Tessitore L, Vizio B, Pesola D, Cecchini F, Mussa A, Argiles JM, et al.:
Adipocyte expression and circulating levels of leptin increase
in both gynaecological and breast cancer patients.  Int J Oncol
2004, 24:1529-1535.
18. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, et al.: Serum levels
of leptin, insulin, and lipids in relation to breast cancer in
china.  Endocrine 2005, 26:19-24.
19. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N,
Trichopoulos D: Leptin and insulin growth factor I in relation
to breast cancer (Greece).  Cancer Causes Control 2000,
11:383-388.
20. Mantzoros CS, Bolhke K, Moschos S, Cramer DW: Leptin in rela-
tion to carcinoma in situ of the breast: a study of pre-meno-
pausal cases and controls.  Int J Cancer 1999, 80:523-526.
21. Yiannakouris N, Yannakoulia M, Melistas L, Chan JL, Klimis-Zacas D,
Mantzoros CS: The Q223R polymorphism of the leptin recep-
tor gene is significantly associated with obesity and predicts
a small percentage of body weight and body composition
variability.  J Clin Endocrinol Metab 2001, 86:4434-4439.
22. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN,
Chouchane L: Leptin and leptin receptor polymorphisms are
associated with increased risk and poor prognosis of breast
carcinoma.  BMC Cancer 2006, 6:38.
23. Woo HY, Park H, Ki CS, Park YL, Bae WG: Relationships among
serum leptin, leptin receptor gene polymorphisms, and
breast cancer in Korea.  Cancer Lett 2006, 237:137-142.
24. Okobia M, Bunker C, Zmuda J, Kammerer C, Vogel V, Uche E, et al.:
Cytochrome P4501A1 genetic polymorphisms and breast
cancer risk in Nigerian women.  Breast Cancer Res Treat 2005,
94:285-293.
25. Okobia MN, Bunker CH, Zmuda JM, Ezeome ER, Anyanwu SN, Uche
EE, et al.: Simple tandem repeat (TTTA)n polymorphism in
CYP19 (aromatase) gene and breast cancer risk in Nigerian
women.  J Carcinog 2006, 5:12.
26. Okobia M, Bunker C, Zmuda J, Kammerer C, Vogel V, Uche E, et al.:
Case-control study of risk factors for breast cancer in Nige-
rian women.  Int J Cancer 2006, 119:2179-2185.
27. Okobia MN, Bunker CH, Zmuda JM, Osime U, Ezeome ER, Anyanwu
SN, et al.: Anthropometry and breast cancer risk in nigerian
women.  Breast J 2006, 12:462-466.
28. Paracchini V, Pedotti P, Taioli E: Genetics of leptin and obesity: a
HuGE review.  Am J Epidemiol 2005, 162:101-114.
29. International HapMap Project   [http://www.hapmap.org/cgi-
perl/snp_details?name=rs1137101&source=hapmap_B36]
30. Chehab FF, Lim ME, Lu R: Correction of the sterility defect in
homozygous obese female mice by treatment with the
human recombinant leptin.  Nat Genet 1996, 12:318-320.
31. Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, Kuijper JL, et
al.: Leptin is a metabolic signal to the reproductive system.
Endocrinology 1996, 137:3144-3147.
32. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier
E, et al.: Role of leptin in the neuroendocrine response to fast-
ing.  Nature 1996, 382:250-252.
33. Mantzoros CS, Flier JS, Rogol AD: A longitudinal assessment of
hormonal and physical alterations during normal puberty in
boys. V. Rising leptin levels may signal the onset of puberty.
J Clin Endocrinol Metab 1997, 82:1066-1070.
34. Mantzoros CS, Moschos SJ: Leptin: in search of role(s) in human
physiology and pathophysiology.  Clin Endocrinol (Oxf) 1998,
49:551-567.
35. Licinio J, Negrao AB, Mantzoros C, Kaklamani V, Wong ML, Bon-
giorno PB, et al.: Synchronicity of frequently sampled, 24-h con-
centrations of circulating leptin, luteinizing hormone, and
estradiol in healthy women.  Proc Natl Acad Sci USA 1998,
95:2541-2546.
36. Carro E, Senaris R, Considine RV, Casanueva FF, Dieguez C: Regu-
lation of in vivo growth hormone secretion by leptin.  Endo-
crinology 1997, 138:2203-2206.
37. Paolisso G, Ammendola S, Del Buono A, Gambardella A, Riondino M,
Tagliamonte MR, et al.: Serum levels of insulin-like growth fac-
tor-I (IGF-I) and IGF-binding protein-3 in healthy centenari-
ans: relationship with plasma leptin and lipid concentrations,
insulin action, and cognitive function.  J Clin Endocrinol Metab
1997, 82:2204-2209.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
Page 8 of 8
(page number not for citation purposes)
38. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM,
Linders TC, et al.: Insulin-like growth-factor-binding protein 3
is decreased in early-stage operable pre-menopausal breast
cancer.  Int J Cancer 1995, 62:266-270.
39. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like
growth factor-I in relation to premenopausal ductal carci-
noma in situ of the breast.  Epidemiology 1998, 9:570-573.
40. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G,
Papapetropoulos A, Sessa WC, et al.: Biological action of leptin as
an angiogenic factor.  Science 1998, 281:1683-1686.
41. Ribatti D, Nico B, Belloni AS, Vacca A, Roncali L, Nussdorfer GG:
Angiogenic activity of leptin in the chick embryo chorioallan-
toic membrane is in part mediated by endogenous fibroblast
growth factor-2.  Int J Mol Med 2001, 8:265-268.
42. Chagnon YC, Chung WK, Perusse L, Chagnon M, Leibel RL, Bouchard
C:  Linkages and associations between the leptin receptor
(LEPR) gene and human body composition in the Quebec
Family Study.  Int J Obes Relat Metab Disord 1999, 23:278-286.
43. Chagnon YC, Wilmore JH, Borecki IB, Gagnon J, Perusse L, Chagnon
M, et al.: Associations between the leptin receptor gene and
adiposity in middle-aged Caucasian males from the HERIT-
AGE family study.  J Clin Endocrinol Metab 2000, 85:29-34.
44. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA Cancer J Clin 2005, 55:74-108.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/338/pre
pub